Blood-tracking device uses new technology

(HealthDay)—The first device to use Radio Frequency Identification (RFID) technology to help workers track blood products and prevent the release of unsuitable samples has been approved by the U.S. Food and Drug Administration.

The iTrace for Blood Centers device uses a memory-storage chip on the item being tracked. In addition to barcode identification systems already in place, the new device provides another layer of protection in product tracking, the agency said in a news release.

The device can track information including a product code, blood type and expiration date, the FDA said.

iTrace is manufactured by SysLogic Inc., based in Brookfield, Wis.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Kcentra approved to stop severe bleeding in heart patients

Apr 30, 2013

(HealthDay)—Kcentra (prothrombin complex concentrate, human) has been approved by the U.S. Food and Drug Administration to treat severe acute bleeding in adults after administration of the anti-clotting drug warfarin and ...

Judges side with FDA in rejecting stem cell device

Mar 22, 2013

(AP)—A federal appeals court is siding with the Food and Drug Administration in a case brought by medical device maker Cytori, ruling that the agency was correct to reject fast-track approval for two company devices used ...

Drug approved for inherited blood disorder

Jan 24, 2013

(HealthDay)—Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.